Primary neuroendocrine invasive breast carcinoma: A case report and literature review
DOI:
https://doi.org/10.7196/SAMJ.2022.v112i11b.16840Keywords:
Breast carcinomaAbstract
Primary neuroendocrine breast cancer (NEBC), also known as breast cancer with neuroendocrine differentiation, comprises a
heterogeneous group of rare invasive breast carcinomas. The diagnosis depends on excluding metastasis from other sites, because the two entities require different management approaches. In this case report, we seek to explore and share our experience of primary NEBC, and provide a literature review.
References
Rosen LE, Gattuso P. Neuroendocrine tumors of the breast. Arch Pathol Lab Med 2017;141(11):1577- 1581. https://doi.org/10.5858/arpa.2016-0364-rs
Trevisi E, la Salvia A, Daniele L, et al. Neuroendocrine breast carcinoma: A rare but challenging entity. Med Oncol 2020;37(8):70. https://doi.org/10.1007/s12032-020-01396-4
Pareja F, D’Alfonso TM. Neuroendocrine neoplasms of the breast: A review focused on the updated World Health Organization (WHO) 5th edition morphologic classification. Breast J 2020;26(6):1160- 1167. https://doi.org/10.1111/tbj.13863
BussolatiG,BadveS.Carcinomaswithneuroendocrinefeatures.In:LakhaniSR,EllisIO,SchnittSJ,Tan PH, van der Vijver MJ, eds. WHO Classification of Tumours of the Breast. Lyon: IARC Press, 2012:62-63. 5. IrelliA,SirufoMM,MorelliL,D’UgoC,GinaldiL,deMartinisM.Neuroendocrinecancerofthebreast:
A rare entity. J Clin Med 2020;9(5):1452. https://doi.org/10.3390/jcm9051452
Özdirik B, Kayser A, Ullrich A, et al. Primary neuroendocrine neoplasms of the breast: Case series and
literature review. Cancers (Basel) 2020;12(3):733. https://doi.org/10.3390/cancers12030733
Lin X, Matsumoto Y, Nakakimura T, et al. Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: A case report and literature review. Surg Case Rep 2020;6(1):143. https://doi.
org/10.1186/s40792-020-00905-x
Tsang JY, Tse GM. Breast cancer with neuroendocrine differentiation: An update based on the latest WHO classification. Mod Pathol 2021;34(6):1062-1073. https://doi.org/10.1038/s41379-021-00736-7
Salemis NS. Primary neuroendocrine carcinoma of the breast: A rare presentation and review of the
literature. Intractable Rare Dis Res 2020;9(4):233-246. https://doi.org/10.5582/irdr.2020.03046
Juhlin CC, Zedenius J, Höög A. Clinical routine application of the second-generation neuroendocrine markers ISL1, INSM1, and secretagogin in neuroendocrine neoplasia: Staining outcomes and potential clues for determining tumor origin. Endocr Pathol 2020;31(4):401-410. https://doi.org/10.1007/s12022-
-09645-y
Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as a biomarker in cardiovascular disease. Biomark Med 2014;8(1):133-140. https://doi.org/10.2217/bmm.13.102
Choudhery S, Xiao L, Zingula S. Review of nonmammary metastases to the breast: Imaging and clinical presentation. Curr Probl Diagn Radiol 2021;50(4):495-498. https://doi.org/10.1067/j. cpradiol.2020.04.010
Chan KH, Lee CH, Sharif SZ, Hayati F, Sallapan S. Diagnostic challenge in diagnosing bilateral breast metastases from mediastinal neuroendocrine tumor: A case report. Ann Med Surg (Lond) 2020;60:438- 441. https://doi.org/10.1016/j.amsu.2020.11.035
Wachter DL, Hartmann A, Beckmann MW, et al. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma. Biomed Res Int 2014;2014:408459. https://doi. org/10.1155/2014/408459
Salemis NS. Primary neuroendocrine carcinoma of the breast: A rare presentation and review of the literature. Intractable Rare Dis Res 2020;9(4):233-246. https://doi.org/10.5582/irdr.2020.03046
Downloads
Published
Issue
Section
License
Copyright (c) 2022 JG Mthembu, MMZU Bhuiyan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
